Cemiplimab
- Generic Name
- Cemiplimab
- Brand Names
- Libtayo
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1801342-60-8
- Unique Ingredient Identifier
- 6QVL057INT
- Background
Cemiplimab is a fully human monoclonal antibody that works against programmed death receptor-1 (PD-1), which is a negative regulator of T cell function. By blocking PD-1, cemiplimab works to enhance T cell-mediated antitumour responses.
...
- Indication
Cemiplimab is indicated to treat:
- Associated Conditions
- Locally Advanced Basal Cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Cervical Cancer, Metastatic Non-Small Cell Lung Cancer, Metastatic cutaneous squamous cell carcinoma, Recurrent Cervical Cancer, Metastatic Basal cell carcinoma
- Associated Therapies
- First Line Chemotherapy
Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-09-10
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05535023
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinProcedure: Computed TomographyOther: Fludeoxyglucose F-18Biological: PembrolizumabDrug: Nab-paclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyBiological: AtezolizumabRadiation: Radiation TherapyOther: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scanBiological: CemiplimabBiological: IpilimumabBiological: Nivolumab
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05501665
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-06-02
- Last Posted Date
- 2023-01-11
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 54
- Registration Number
- NCT05401786
- Locations
- 🇳🇱
Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands
Study of Cemiplimab - TP Induction Chemotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck
- Conditions
- Interventions
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Krzysztof Misiukiewicz
- Target Recruit Count
- 24
- Registration Number
- NCT05376553
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in Europe
- Conditions
- Interventions
- First Posted Date
- 2022-05-05
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 500
- Registration Number
- NCT05363319
- Locations
- 🇫🇷
Investigational Site Number: 250-004, Marseille, Bouches-du-Rhône, France
🇩🇪Investigational Site Number: 276-012, Georgsmarienhütte, Niedersachsen, Germany
🇩🇪Investigational Site Number: 276-009, Troisdorf, Nordrhein-Westfalen, Germany
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
- Conditions
- Interventions
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 1535
- Registration Number
- NCT05352672
- Locations
- 🇺🇸
Atlantic Health System - Morristown Medical Center, Morristown, New Jersey, United States
🇦🇷Fundacion Cenit para la Investigacion en Neurociencias, Buenos Aires, Argentina
🇦🇷DIABAID - Instituto de Asistencia Integral en Diabetes, Buenos Aires, Argentina
Comparative Efficacy of Cemiplimab to Historical Standard of Care in France
- First Posted Date
- 2022-03-31
- Last Posted Date
- 2022-12-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 305
- Registration Number
- NCT05302297
A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab
- Conditions
- Interventions
- First Posted Date
- 2022-02-28
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 50
- Registration Number
- NCT05259709
- Locations
- 🇳🇱
UMC Groningen, Groningen, Netherlands
THIO Sequenced with Cemiplimab in Advanced NSCLC
- Conditions
- Interventions
- First Posted Date
- 2022-01-26
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Maia Biotechnology
- Target Recruit Count
- 182
- Registration Number
- NCT05208944
- Locations
- 🇧🇬
MHAT "Serdika" EOOD, Sofia, Bulgaria
🇧🇬UMHAT "Sofiamed", Sofia, Bulgaria
🇦🇺Sunshine Coast Haematology and Oncology Clinic, Buderim, Queensland, Australia
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients with Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-12-02
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- BioNTech SE
- Target Recruit Count
- 160
- Registration Number
- NCT05142189
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸NEXT Virginia, Fairfax, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.